 And so in the case that you were just telling us about in terms of the determination to go away from post-transplant drugs and toward rheumatoid arthritis, explain why that's different for the drug developer. It's simply because there's no FDA nod of approval on that, so there's more money in the rheumatoid arthritis end of things?